Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience

Canadian Urological Association Journal

Volumn 8, Issue 3-4, 2014, Pages e287-e293

  El Gehani, Faraj ^a   North, Scott ^b   Ghosh, Sunita ^b   Venner, Peter ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899927032     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.1643     Document Type: Article

References (22)

1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1, 054 patients. J Clin Oncol 2001;19:666-75.
2. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience. Cancer 2008;113:2471-7. http://dx.doi.org/10.1002/cncr.23848.
3. Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 2012;61:1229-38. http://dx.doi.org/10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.
4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66. http://dx.doi.org/10.1056/NEJMoa022148.
5. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group et al: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171-7. http://dx.doi.org/10.1200/JCO.2010.32.3139.
6. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neo adjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202-6. http://dx.doi.org/10.1016/j.eururo.2005.04.006.
7. Bellmunt J, Orsola A, Maldonado X, et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5): 134-6. http://dx.doi.org/10.1093/annonc/mdq175
8. National Comprehensive Cancer Care Network: NCCN clinical practice guidelines in oncology: bladder cancer including upper tract tumours and urothelial carcinoma of the prostate. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#bladder(Accessed April 7, 2014; free registration required).
9. Miles BJ, Fairey AS, Eliasziw M, et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010;4:263-7. http://dx.doi.org/10.5489/cuaj09134.
10. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
11. Kaneko G, Kikuchi E, Matsumoto K, et al. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. Jpn J Clin Oncol 2011;41:908-14. http://dx.doi.org/10.1093/jjco/hyr068.
12. Fairey AS, Jacobsen NE, Chetner MP, et al. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: Results from the Alberta Urology Institute Radical Cystectomy database. J Urol 2009;182:85-92. http://dx.doi.org/10.1016/j.juro.2008.11.111.
13. Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 2002;41:440-8. http://dx.doi.org/10.1016/S0302-2838(02)00060-X.
14. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur Urol 2004;45:297-303. http://dx.doi.org/10.1016/j.eururo.2003.09.019.
15. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117:276-82. http://dx.doi.org/10.1002/cncr.25429.
16. Bajorin DF, Herr HW. Kuhn's paradigms: Are those closest to treating bladder cancer the last to appreciate the paradigm shift? J Clin Oncol 2011;29:2135-7. http://dx.doi.org/10.1200/JCO.2010.34.0471.
17. Mertens LS, Meijer RP, Kerst JM, et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer-a reasonable alternative for cisplatin unfit patients? J Urol 2012;188:1108-14. http://dx.doi.org/10.1016/j.juro.2012.06.018.
18. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial., . Lancet 1999;354:533-40. http://dx.doi.org/10.1016/S0140-6736(99)02292-8.
19. Canter D, Viterbo R, Kutikov A, et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011;77:160-5. http://dx.doi.org/10.1016/j.urology.2010.03.091.
20. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115:4104-9. http://dx.doi.org/10.1002/cncr.24466.
21. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: A contemporary series. J Urol 2001;165:1111-6. http://dx.doi.org/10.1016/S0022-5347(05)66440-3.
22. Mertens LS, Meijer RP, Meinhardt W, et al. Occult lymph node metastases in patients with muscle invasive bladder cancer: Incidence after neo adjuvant chemotherapy and cystectomy versus cystectomy alone. BJU Int 2013. http://dx.doi.org/10.1111/bju.12447.